Skip to Content

Manageable safety profile and promising efficacy in heavily pretreated patients with R/R Non-Hodgin Lymphoma

In this MEDtalk, Jean Marie Michot, MD, Paris, presents insights from poster S216  at EHA22, where a Cereblon E3 Ligase Modulator agent in monotherapy demostrate a showed a manageable safety profile and promising efficacy in heavily pretreated patients with R/R Non-Hodgin Lymphoma.

Jean-Marie Michot

Få adgang til artiklen

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top